Wednesday, 14 October 2026European Markets

TIETOEVRY, NEDAP, Another 2 Companies Have A High Dividend Yield And Return On Equity In The Information Technology Services Industry.

Loading stream...

(VIANEWS) - TIETOEVRY (TIETO.OL) is among this list of stock assets with the highest dividend rate and return on equity on the Information Technology Services industry.

Financial Asset Price Forward Dividend Yield Return on Equity
TIETOEVRY (TIETO.OL) kr212.80 7.39% 10.34%
NEDAP (NEDAP.AS) €61.80 5.13% 25.89%
BOUVET (BOUV.OL) kr60.60 4.08% 60.9%
SONAECOM,SGPS (SNC.LS) €2.52 1.21% 3.64%

Several Euronext companies pay out dividends to its shareholders. The dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.

1. TIETOEVRY (TIETO.OL)

7.39% Forward Dividend Yield and 10.34% Return On Equity

TietoEVRY Oyj operates as a software and services company. It operates through five segments: Tietoevry Create, Tietoevry Banking, Tietoevry Care, Tietoevry Industry, and Tietoevry Tech Services. The Tietoevry Create segment provides digital agenda to create competitive products, as well as uses design, data, and cloud technologies for data-driven businesses. This segment also offers software and data engineering services. The Tietoevry Banking segment provides Banking-as-a-Service platform and software products for digital transformation and financial institutions. The Tietoevry Care segment offers modular and interoperable software, reinventing Nordic health, and social care services. The Tietoevry Industry segment offers software and data solutions to various industries, such as public sector, pulp and paper, and utilities. The Tietoevry Tech Services provides enterprise-wide transformation to customers' business processes, applications and infrastructure; and deep customer knowledge, global cloud & data competencies, automated operations, and multi-cloud platform services. The company was formerly known as Tieto Oyj and changed its name to TietoEVRY Oyj in December 2019. TietoEVRY Oyj was incorporated in 1968 and is headquartered in Espoo, Finland.

Earnings Per Share

As for profitability, TIETOEVRY has a trailing twelve months EPS of kr16.14.

PE Ratio

TIETOEVRY has a trailing twelve months price to earnings ratio of 13.18. Meaning, the purchaser of the share is investing kr13.18 for every norwegian krone of annual earnings.

Return on Equity

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 10.34%.

More news about TIETOEVRY.

2. NEDAP (NEDAP.AS)

5.13% Forward Dividend Yield and 25.89% Return On Equity

Nedap N.V., together with its subsidiaries, develops and supplies technological solutions in the Netherlands, Germany, rest of Europe, North America, and internationally. It offers software services, which allow healthcare institutions in planning, registering, and administering care; iD Cloud App, a RFID solutions for inventory management, simplified shop processes, and prevention of shrinkage; and technological solutions for individual animal monitoring and management for the dairy farming industry. The company also develops access control and security systems for companies and institutions. Nedap N.V. was founded in 1929 and is headquartered in Groenlo, the Netherlands.

Earnings Per Share

As for profitability, NEDAP has a trailing twelve months EPS of €3.29.

PE Ratio

NEDAP has a trailing twelve months price to earnings ratio of 18.78. Meaning, the purchaser of the share is investing €18.78 for every euro of annual earnings.

Return on Equity

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 25.89%.

More news about NEDAP.

3. BOUVET (BOUV.OL)

4.08% Forward Dividend Yield and 60.9% Return On Equity

Bouvet ASA provides IT and digital communication consultancy services for public and private sector companies in Norway, Sweden, and internationally. The company was incorporated in 1995 and is headquartered in Oslo, Norway.

Earnings Per Share

As for profitability, BOUVET has a trailing twelve months EPS of kr3.13.

PE Ratio

BOUVET has a trailing twelve months price to earnings ratio of 19.36. Meaning, the purchaser of the share is investing kr19.36 for every norwegian krone of annual earnings.

Return on Equity

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 60.9%.

Dividend Yield

As claimed by Morningstar, Inc., the next dividend payment is on May 24, 2023, the estimated forward annual dividend rate is 2.5 and the estimated forward annual dividend yield is 4.08%.

More news about BOUVET.

4. SONAECOM,SGPS (SNC.LS)

1.21% Forward Dividend Yield and 3.64% Return On Equity

Sonaecom, S.G.P.S., S.A., together with its subsidiaries, operates in technology, media, and telecommunications areas worldwide. The company provides consultancy services in the area of information systems; sells licensed software; and research, development, consulting, maintenance, and audit services for products, systems, facilities, and communication and security services. It also engages in the editing, composition, and publication of periodical and non-periodical materials, as well as exploration of radio and TV stations and studios; consulting, advisory, audit, and maintenance of various facilities, and communication services and security systems; and purchase and installation of communication and security systems. In addition, the company is involved in the research, development, and commercialization of projects and service solutions in the area of information technology, communications and retail, and consulting activities for business and management; development, installation, implementation, training, and maintenance of systems and software products; rental of equipment; consulting business; industries and trade of electronic equipment and software; and advisory in retail segments, and industries and services. Further, it provides support, management consulting, and administration, primarily in the areas of accounting, taxation, administrative procedures, logistics, human resources, and training; and services in IT and cybersecurity to institutions, banks, and insurance companies, as well as invests in and manages venture capital and venture capital funds. The company was founded in 1988 and is headquartered in Cidade da Maia, Portugal. Sonaecom, S.G.P.S., S.A. operates as a subsidiary of Sontel B.V.

Earnings Per Share

As for profitability, SONAECOM,SGPS has a trailing twelve months EPS of €0.14.

PE Ratio

SONAECOM,SGPS has a trailing twelve months price to earnings ratio of 18. Meaning, the purchaser of the share is investing €18 for every euro of annual earnings.

Return on Equity

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 3.64%.

Moving Average

SONAECOM,SGPS's value is higher than its 50-day moving average of €2.46 and higher than its 200-day moving average of €2.43.

Earnings Before Interest, Taxes, Depreciation, and Amortization

SONAECOM,SGPS's EBITDA is 108.55.

Revenue Growth

Year-on-year quarterly revenue growth grew by 6%, now sitting on 19.67M for the twelve trailing months.

More news about SONAECOM,SGPS.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,375 source documents archived
Query this data → isubstrate.com